NOT FOR CLINICAL USE / SYNTHETIC DEMO — Not medical advice. Not FDA-cleared. Gate 3 is not signed. Predicted odds are from published studies only.
Workspace · Cancer algorithms · Female breast
Female breast · 321,910 new · 42,140 deaths (ACS 2026) · mortality 18.9 per 100k · 5-yr RS 91.9% (SEER)
Mortality 18.9 per 100k (SEER / ACS common-sites). Never an artboard percent.
Birth-to-death 13.0% (1 in 8) among females (ACS Table 6). Plus 2,670 male cases (ACS 2026).
4,238,585 women living with this cancer in 2023 (SEER Stat Facts). Population count only — not a personal risk.
Median age at diagnosis 64 · at death 71 (SEER Stat Facts). SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Population median — not a personal risk.
Incidence women 132.5 per 100k · mortality women 18.9 per 100k. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. All races, age-adjusted per 100k — never an artboard percent.
Most often diagnosed among women aged 65–74. Deaths highest among women aged 65–74. SEER 21 2019–2023 diagnosis; U.S. 2020–2024 death. Modal age group only — not a screening age and not a personal risk.
New cases rising 0.7% each year (2014–2023). Death rates falling 1.2% each year (2015–2024). Official Stat Facts Joinpoint sentence. Population trend — not a personal risk and not a screening interval.
Highest new-case rate: Non-Hispanic White women 141.3 per 100k. Highest death rate: Non-Hispanic Black women 25.9 per 100k. Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
Race/ethnicity rates per 100k (SEER Stat Facts)
| Group | Inc. men | Inc. women | Deaths men | Deaths women |
|---|---|---|---|---|
| Hispanic | — | 107.9 | — | 13.4 |
| Non-Hispanic American Indian/Alaska Native | — | 119.4 | — | 16.9 |
| Non-Hispanic Asian/Pacific Islander | — | 116.5 | — | 11.8 |
| Non-Hispanic Black | — | 132.4 | — | 25.9 |
| Non-Hispanic White | — | 141.3 | — | 19.1 |
Official Stat Facts race/ethnicity rates. SEER 21 2019–2023 incidence; U.S. 2020–2024 mortality. Age-adjusted per 100k — never an artboard percent. Cells not shown on Stat Facts (<16 cases) stay blank.
USPSTF screening pointer
USPSTF 2024 B · Women 40–74 · Mammography
Encoded on the published track as an eligibility table — not a personal recommendation. USPSTF-breast-2024
ACS early-detection pointer
ACS 2026 · Women at average risk · ACS: choice to start annual mammograms at 40–44; yearly at 45–54; at 55+ every 2 years or continue yearly. This demo encodes USPSTF 2024 biennial 40–74. Not equivalent.
Cited ACS statement only. Do not claim USPSTF / NCCN equivalence. ACS-early-detection
USPSTF risk-assessment pointer
USPSTF 2019 B/D · Women with or without familial or ancestry clues for BRCA1/2 · USPSTF 2019 Grade B: assess women with personal or family history of breast, ovarian, tubal, or peritoneal cancer, or ancestry associated with BRCA1/2, with a brief familial risk tool — then counseling and testing if indicated. Grade D against routine assessment when history and ancestry are not associated. Named tools are not encoded. Tyrer-Cuzick remains needs-license. Not a mammography interval.
Cited familial-risk statement only. Not a screening interval and not a scoring engine. USPSTF-brca-2019
Surveillance pointer
ASCO-survivorship cited · cited only · ASCO survivorship class after a breast finding. No invented residual-lifetime percent. No unpublished interval and no invented month table.
Named public source only. Not a personal follow-up calendar. ASCO-survivorship
Surveillance pointer
ACS-breast-follow 2026 · cited only · ACS living-as-a-survivor page names typical follow-up visits every 3 to 6 months at first, then about yearly after 5 years, plus mammograms after breast-conserving surgery. Those months are not encoded. Complementary to the ASCO-class pointer. No invented residual-lifetime percent.
Named public source only. Not a personal follow-up calendar. ACS-breast-follow
Surveillance pointer
ACS-breast-second 2026 · cited only · ACS second-cancers page says other than standard early detection screenings, most experts do not recommend any additional testing to look for second cancers in breast cancer survivors unless you have symptoms. Complementary to the ASCO first row and the ACS living-as row. Official second-cancer risk figures are not restated. Not a second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-breast-second
Surveillance pointer
ACS-long-term-effects 2025 · cited only · ACS long-term page names a cancer treatment summary and survivorship care plan, plus cancer-related fatigue, osteopenia or osteoporosis after hormone-affecting treatment, and lymphedema after node surgery or radiation. Those names are not encoded. Complementary to the ASCO-class pointer and the ACS living-as / second-cancer rows. Not a DXA-interval or lymphedema-stage engine.
Named public source only. Not a personal follow-up calendar. ACS-long-term-effects
Surveillance pointer
ACS-follow-up-care 2025 · cited only · ACS follow-up-care page names echoes after cardiotoxic chemo and yearly mammograms plus breast MRIs after chest radiation before age 30, plus a treatment summary and survivorship care plan. Those named tests and plans are not encoded. Complementary to the breast printout and the COG / ASCO first row. Not a DXA-interval or second-primary screening engine.
Named public source only. Not a personal follow-up calendar. ACS-follow-up-care
Toxicity pointer
COG-LTFU cited · encoded flag · COG / ASCO-class earlier breast imaging after chest radiation. Flags only. No dose reconstruction.
Named public source only. Flags are not dose reconstruction. COG-LTFU
Toxicity pointer
ACS-breast-follow 2026 · empty on purpose · ACS living-as-a-survivor page names late and long-term side effects after breast-cancer treatment. Those late effects are not encoded. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-breast-follow
Toxicity pointer
ACS-breast-second 2026 · empty on purpose · ACS second-cancers page names later cancers after breast-cancer treatment. Those second-cancer risks are not encoded. Complementary to the encoded COG / ASCO flags. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-breast-second
Toxicity pointer
ACS-long-term-effects 2025 · empty on purpose · ACS long-term page names later heart problems after chest or breast radiation, cancer-related fatigue, osteoporosis, and lymphedema. Those late effects are not encoded. Complementary to the encoded COG / ASCO flags. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-long-term-effects
Toxicity pointer
ACS-follow-up-care 2025 · empty on purpose · ACS follow-up-care page names echoes after cardiotoxic chemo and yearly mammograms plus breast MRIs after chest radiation before age 30. Those named tests are not encoded. Complementary to the COG / ASCO first row. Empty on purpose.
Named public source only. Flags are not dose reconstruction. ACS-follow-up-care
Late toxicity printout
Late toxicity printout — Breast
Acute: ACS names fatigue, field skin change, soreness, and swelling during breast RT. Late: skin and size change, heart and lung problems, uncommon rib fracture, lasting fatigue, bone loss after hormone-affecting treatment, low estrogen or testosterone, lymphedema, jaw osteonecrosis after bisphosphonates, neuropathy after chemo, cognitive change after chemo, and vision change after hormone therapy. Monitor: new breast change after about a year; echoes after cardiotoxic chemo; yearly mammograms plus breast MRIs after chest radiation before age 30; lasting fatigue or sleep problems; dental check before bisphosphonates; numbness or tingling after chemo; memory, thinking, or focus change after chemo; vision change after hormone therapy. Those names are not encoded. Not a DXA-interval, Lung-RADS, or second-primary screening engine.
Questions to ask
ACS long-term page lists questions to ask the care team: possible long-term and late effects, whether fertility or second-cancer risk is higher, which cancer screening tests belong later, which specialists should follow those effects, whether cancer rehabilitation could help, and when to call primary care versus cancer care. Those questions are not encoded. Not a screening, fertility, rehab, or specialist-interval engine.
ACS long-term page says not everyone who has cancer treatment gets long-term or late effects. Who does can depend on the cancer type, the type and dose of treatment, side effects during treatment, age at diagnosis, health before treatment, genetics, eating and exercise during and after treatment, care-team expertise, and support from others. Those reasons are not encoded. Not a late-effect risk-score engine.
ACS follow-up-care page lists questions to ask: how to get a treatment summary and follow-up care plan, who is in charge of follow-up, how often visits and which tests or screens belong later, signs of recurrence or a second cancer, and which survivor support services are available. Follow-up may stay with the cancer care team, move to a survivorship clinic, or return to primary care, depending on the cancer type and stage, the treatment, remaining side effects, insurance, and wishes. Those questions and choices are not encoded. Not a visit-interval, screening, or clinic-routing engine.
Treatment summary and care plan
ACS follow-up-care page names what a cancer treatment summary most often includes: diagnosis date; cancer type, including where it started, stage, and grade if known; treatments and dates, including type, dose, and number of cycles; side effects and how they were managed; test results; and names and contacts for the treating doctors. A survivorship care plan most often names remaining treatment, how often follow-up should happen, which tests including screens for other cancers, possible long-term or late effects, and ways to improve overall health. Those named contents are not encoded. Not a records, visit-interval, or screening engine.
How late effects are managed
ACS follow-up-care page says long-term side effects begin during treatment and continue after, and late side effects can start months or years later. Follow-up care may include a review of symptoms, a physical exam, blood tests to check blood counts and how the liver, kidneys, and other organs are working, and other tests as needed. Special tests after some treatments stay named on this printout. Those named steps are not encoded. Not a lab-panel, visit-interval, or screening engine.
ACS long-term late names
ACS follow-up tests named here
Echoes after cardiotoxic chemo · Yearly mammograms plus breast MRIs after chest radiation before age 30
Named conditions to monitor
Acute toxicities · Late toxicities · Named conditions to monitor. Cadences are placeholders. Named tests are not encoded. Cited ACS / COG / ASCO names only. Complementary ACS long-term page is named, not encoded. Not a lymphedema stage engine. Not dose reconstruction. No invented trial percent.
Open Breast printout →NOT FOR CLINICAL USE / SYNTHETIC DEMO — Educational estimates only. Not FDA-cleared. Not a diagnosis.
algo-breast · approximation · evaluateBreast · Gail-class-approx
SEER 5-year relative survival by stage
Localized 99.6% · Regional 86.7% · Distant 31.9% · All 91.9%
Female breast. SEER Cancer Stat Facts.
Percent of cases by stage (SEER Stat Facts)
Localized 64% · Regional 27% · Distant 6% · Unknown 2%
Percent of cases at diagnosis — not 5-year relative survival. SEER Combined Summary Stage. Female breast.
age-interval
Female breast birth–49 / 50–64 / 65–84
2.2% / 4.0% / 7.3%
lifetime
Female breast birth-to-death
13.0% (1 in 8)
5-year
Gail-class educational 5-year (fixture-dependent)
ACS Table 6 baseline × RR
Screening · Surveillance · Toxicity on four golden fixtures
Rio · Plan — survivor
0.67 educational %relative risk ×1.21 · USPSTF 2024 biennial mammography 40–74
screening
USPSTF 2024 biennial mammography 40–74
USPSTF 2024 biennial mammography discussion 40–74 — not official BCRAT
on this plan
surveillance
Atypical hyperplasia / clinic-directed watch
No invented residual-lifetime % after a finding. Tyrer-Cuzick is a named stub only.
empty on purpose
toxicity
Treatment-related breast after chest RT
Earlier breast imaging flag after chest RT — no dose reconstruction
on this plan
Noah · Plan — skin cancer
—Gail-class model is defined for women without a personal invasive-breast-cancer history
screening
USPSTF 2024 biennial mammography 40–74
Gail-class model is defined for women without a personal invasive-breast-cancer history
out of domain
surveillance
Atypical hyperplasia / clinic-directed watch
No invented residual-lifetime % after a finding. Tyrer-Cuzick is a named stub only.
out of domain
toxicity
Treatment-related breast after chest RT
No chest-RT breast late-effect flag on this fixture
out of domain
Walter · S1 prostate
—Gail-class model is defined for women without a personal invasive-breast-cancer history
screening
USPSTF 2024 biennial mammography 40–74
Gail-class model is defined for women without a personal invasive-breast-cancer history
out of domain
surveillance
Atypical hyperplasia / clinic-directed watch
No invented residual-lifetime % after a finding. Tyrer-Cuzick is a named stub only.
out of domain
toxicity
Treatment-related breast after chest RT
No chest-RT breast late-effect flag on this fixture
out of domain
Priya · average-risk
0.61 educational %relative risk ×1.10 · USPSTF 2024 biennial mammography 40–74
screening
USPSTF 2024 biennial mammography 40–74
USPSTF 2024 biennial mammography discussion 40–74 — not official BCRAT
on this plan
surveillance
Atypical hyperplasia / clinic-directed watch
No invented residual-lifetime % after a finding. Tyrer-Cuzick is a named stub only.
empty on purpose
toxicity
Treatment-related breast after chest RT
No chest-RT breast late-effect flag on this fixture
empty on purpose
NOT official BCRAT. The composed 15-screen evidence figure stays on the artboard and is not recomputed here.